IFOSFAMIDE PLUS DOXORUBICIN IN METASTATIC ADULT SARCOMAS - A MULTI-INSTITUTIONAL PHASE-II TRIAL

被引：66

作者：

LOEHRER, PJ

SLEDGE, GW

NICAISE, C

USAKEWICZ, J

HAINSWORTH, JD

MARTELO, OJ

OMURA, G

BRAUN, TJ

机构：

[1] BRISTOL MYERS CO,WALLINGFORD,CT

[2] UNIV CINCINNATI,CINCINNATI,OH 45221

[3] UNIV ALABAMA,BIRMINGHAM,AL

[4] VANDERBILT UNIV,NASHVILLE,TN 37240

[5] UNIV COLORADO,DENVER,CO 80202

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1989年 / 7卷 / 11期

关键词：

D O I：

10.1200/JCO.1989.7.11.1655

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1655 / 1659

页数：5

共 31 条

[1]

ANTMAN K, 1989, CANCER PRINCIPLES PR, P1345

[2]

BARNETT D, 1982, SEMIN ONCOL, V9, P8

[3]

BORDEN EC, 1983, P AN M AM SOC CLIN, V2, P231

[4] IFOSFAMIDE - PHARMACOLOGY, SAFETY AND THERAPEUTIC POTENTIAL [J].

BRADE, WP ;

HERDRICH, K ;

VARINI, M .

CANCER TREATMENT REVIEWS, 1985, 12 (01) :1-47

[5] CYCLOPHOSPHAMIDE VERSUS IFOSFAMIDE - FINAL REPORT OF A RANDOMIZED PHASE-II TRIAL IN ADULT SOFT-TISSUE SARCOMAS [J].

BRAMWELL, VHC ;

MOURIDSEN, HT ;

SANTORO, A ;

BLACKLEDGE, G ;

SOMERS, R ;

VERWEY, J ;

DOMBERNOWSKY, P ;

ONSRUD, M ;

THOMAS, D ;

SYLVESTER, R ;

VANOOSTEROM, A .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (03) :311-321

[6]

BROCK N, 1979, ARZNEIMITTEL-FORSCH, V29-1, P659

[7]

BROCK N, 1972, ADV ANTIMICROBIAL AN, V2, P749

[8] A CONFIDENCE-INTERVAL FOR THE MEDIAN SURVIVAL-TIME [J].

BROOKMEYER, R ;

CROWLEY, J .

BIOMETRICS, 1982, 38 (01) :29-41

[9]

BRYANT BM, 1980, LANCET, V2, P657

[10] DOXORUBICIN IN DISSEMINATED OSTEOSARCOMA [J].

CORTES, EP ;

HOLLAND, JF ;

SINKS, LF ;

WANG, JJ .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1972, 221 (10) :1132-&

← 1 2 3 4 →